% | $
Quotes you view appear here for quick access.

Abbott Laboratories Message Board

  • futureripplemovers futureripplemovers Jan 22, 2014 8:28 AM Flag

    Abbott Reports Fourth-Quarter and Full-Year 2013 Results

    Abbott Reports Fourth-Quarter and Full-Year 2013 Results
    Fourth-Quarter Ongoing EPS of $0.58 (GAAP EPS From Continuing Operations of $0.37)
    Achieved Adjusted Operating Margin Improvement in 2013
    Launched Multiple New Products in 2013 Across Diverse Business Portfolio
    Issues Earnings Outlook for 2014
    Date: January 22, 2014

    Abbott Park, Illinois (NYSE: ABT) — Abbott today announced financial results for the fourth quarter ended Dec. 31, 2013.

    Ongoing diluted EPS was $0.58 in the fourth quarter and $2.01 for the full year, reflecting double-digit growth; reported diluted EPS from continuing operations under GAAP was $0.37 in the fourth quarter and $1.50 for the full year.
    Excluding foreign exchange, fourth-quarter worldwide sales increased 3.3 percent on an operational basis. Reported sales increased 0.4 percent, including an unfavorable 2.9 percent effect of foreign exchange. The previously reported sales disruption in International Nutrition that occurred in August is estimated to have reduced Abbott's total worldwide sales growth by approximately 1.5 percentage points.
    For the full-year 2013, Abbott expanded its adjusted operating margin by 110 basis points over prior year. This was primarily driven by continuing improvements in Diagnostics and Nutrition. Operating margin under GAAP improved by 320 basis points over prior year.
    In 2013, Abbott delivered on a number of new product launches. Highlights include nearly 70 new product launches in Nutrition; XIENCE Xpedition™ drug-eluting stent in the United States and Japan; MitraClip®, Abbott's first-in-class device for the treatment of mitral regurgitation, in the United States; TECNIS® OptiBlue intraocular lens (IOL) in Japan and TECNIS Toric IOL in the United States; ACCELERATOR a3600™, a next-generation automation solution for the core laboratory; and several new diagnostic tests on the ARCHITECT™ platform.
    Abbott issues ongoing EPS guidance for the full-year 2014 that reflects double-digit g

39.30+0.41(+1.05%)May 27 4:02 PMEDT